Previous studies demonstrated either antidiabetic or antihyperlipidemic effects of Moringa oleifera using extracts or leaf powders in separate mouse models. However, evidence regarding the therapeutic efficacy of fresh Moringa oleifera leaf juice as a dietary supplement remains limited, particularly in a combined diet and STZ-NA (streptozotocin–nicotinamide)-induced hyperlipidemia and type 2 diabetes in a mouse model. This study focuses on the long-term dietary supplementation with fresh moringa leaf juice in patients with concurrent type 2 diabetes and hyperlipidemia. A total of eighty (80) Swiss albino mice were used, with forty (40) randomly divided into four equal groups for diabetes induction and proof of concept for hypoglycemic activity, considered as Trial 1, and the remaining 40 were divided into another four groups for combined induction of hyperlipidemia and diabetes, as Trial 2. The mouse group for both trials was named T0 (diabetic control), and the treatment groups were T1, T2, and T3, supplemented with fresh moringa leaf juice at 2, 3, and 4 mL/100 mL of drinking water, respectively, for 12 weeks. In Trial 1, blood glucose levels decreased significantly (P<0.05) to 8.46, 8.62, and 9.2 mmol/L in T1, T2, and T3, respectively, compared with the control group mice. In Trial 2 (diabetic hyperlipidemic mice), triglycerides (TG), low-density lipoprotein (LDL), cholesterol, and blood glucose decreased significantly (P<0.05) in T1, T2, and T3 compared with the control group. High-density lipoprotein (HDL) increased significantly (P<0.05) in the treatment groups compared with the control group. These findings extend current evidence by highlighting that long-term dietary supplementation with fresh Moringa leaf juice improves both hyperglycemia and dyslipidemia in a combined metabolic disease model.